Tight-junction regulator studied for celiac disease and leaky-gut symptoms.
Typical dose range: 0.25–1 mg
Frequency: 3x daily before meals
Route: Oral
Half-life: ~2 hours
Evidence level: Phase 3 (mixed)
Failed its primary Phase 3 endpoint for celiac in 2022 but is still researched for general intestinal permeability.